INTRODUCTION
Vanadate has been reported to promote the formation of elevated levels of proteins phosphorylated on tyrosine residues [1] [2] [3] [4] [5] [6] . This may be a consequence of protein phosphatase inhibition [7] and\or protein kinase stimulation [8] . Evidence for the former is supported by the structural similarity between vanadate and the presumed transition state in phosphomonoester hydrolysis [9, 10] . In addition, studies with highly purified insulin receptors support a role for vanadate as a tyrosine kinase stimulator, and a molecular mechanism that accounts for this behaviour has been proposed [7] . This mechanism suggests that there are significant differences in the responses of protein tyrosine kinases and protein serine\threonine kinases to vanadate. However, very few experimental studies on purifed enzyme systems have been reported, and none have been described with serine\threonine protein kinases. The present paper describes the effects of vanadate and other vanadium species on the catalytic activity of the purified catalytic subunit of the cAMP-dependent protein kinase (PKA).
There are several different mechanisms by which vanadate can interact with proteins [11] . First, vanadate is both structurally and electronically analogous to the presumed transition-state structure associated with phosphate monoester hydrolysis. In its capacity as a transition-state analogue, vanadate inhibits reactions catalysed by a variety of ATPases, phosphatases and ribonucleases [12] . Secondly, vanadate can act by forming substrate or cofactor analogues that are structurally related to endogenous phosphate-bearing substrates. For example, vanadate will combine with aliphatic and aromatic alcohols to form vanadate esters, derivatives that can participate in some enzymeAbbreviation used : PKA, cAMP-dependent protein kinase. ‡ To whom correspondence should be addressed.
the enzyme that accommodates the positively charged kemptide substrate. Our studies suggest that decavanadate can associate with kemptide in solution, which would prevent kemptide from interacting with the enzyme. Vanadium(IV) also inhibits the PKA-catalysed phosphorylation of kemptide, but with an IC &! of 366p10 µM. However, in this case V% + appears to bind to the Mg# + -binding site, since it can substitute for Mg# + . In the absence of Mg# + , the optimal concentration of vanadium(IV) for the PKA-catalysed phosphorylation of kemptide is 100 µM, with concentrations above 100 µM being markedly inhibitory. However, even at the optimal 100 µM V% + concentration, the V max and K m values (for kemptide) are significantly less favourable than those obtained in the presence of 100 µM Mg# + . In summary, we have found that oxovanadium ions can directly alter the activity of the serine\threonine-specific PKA.
catalysed reactions [13] [14] [15] . Thirdly, vanadate forms oligomeric anions at physiological pH that are also capable of interacting with enzymes [11] . Decavanadate (HV "! O #) &−) is generated in solution when the pH falls below 5.5 [16] ; however, it is sufficiently inert at neutral pH for in itro studies. Decavanadate is known to inhibit kinases such as hexokinase, adenylate kinase and phosphofructokinase [17] . Fourthly, vanadate has been demonstrated to oxidize enzymes, resulting in their inactivation [18] . Finally, the vanadyl cation is also capable of acting as a bivalent cation mimic. In this capacity, the vanadyl cation can promote enzymic activity in the absence of the natural metal ion [9, 10, 18] , or can inhibit activity by competing with the endogenous bivalent cation for the active site, thereby decreasing the rate of catalytic turnover [14, 19] . With these possibilties in mind, we have examined the effects exerted by several of these vanadium oxoion derivatives on the catalytic activity of PKA.
EXPERIMENTAL Materials
Chemicals were obtained from Aldrich, except for [γ-$#P]ATP (New England Nuclear), ATP (Sigma), cAMP (Fluka), protected amino acid derivatives (U.S. Biochemical) and scintillation cocktail (National Diagnostics). Phosphocellulose P81 paper discs were purchased from Whatman. Fresh bovine hearts were acquired from Klinck Brothers, Buffalo, NY, U.S.A. The catalytic subunit of PKA was isolated as previously described [20] .
Radioactivity in samples was counted in Liquiscint (National Diagnostics) and quantified in a Beckman LS-5000TD liquid scintillation counter. Buffers were prepared using laboratory distilled water that was purified further through a Waters Milli-Q system. Kemptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly) was synthesized using standard solid-phase peptide synthesis methodology [20] .
Vanadium oxoion stock solutions
Vanadate solutions were prepared by dissolving known amounts of sodium orthovanadate (in solid form ; NaVO $ ) in distilled deionized water up to either 0.25 M or 1.0 M. The vanadate solutions were unadjusted for pH and stored at 4 mC. Vanadyl sulphate was dissolved in 0.1 M HCl and stored at 4 mC. Vanadate decamer was prepared immediately prior to use by slowly adding 190 µl of 6 M HCl to 500 µl of the 1.0 M vanadate stock solution to a final pH of 2.4. The vanadium (j5) species present in assay solutions can be determined using &"V NMR spectroscopy as described previously [21] . Under the conditions employed in this work, vanadate dimer and tetramer emerge between 0.2 and 0.3 mM total vanadate. Vanadate tetramer will be the major V(V) species above 1 mM total vanadate. Since no inhibition by vanadate was observed, additional details on vanadate speciation under these conditions proved to be unnecessary.
Kinase assay
Assays were performed in triplicate at pH 7.1 in a water bath thermostatted at 30 mC. The assays were conducted in 12 mmi75 mm polystyrene test tubes in a final volume of 100 µl. Unless otherwise noted, the assays contained 100 mM Mops, 150 mM KCl, 12. Reactions were quenched after a given time period (4.5 or 6 min) by spotting 25 µl aliquots on to 2.1 cm diameter phosphocellulose paper discs. After 10 s the discs were immersed in 10 % acetic acid (20 ml\disc) and allowed to soak with occasional stirring for at least 1 h. After decantation of the acetic acid, the discs were washed with 4 vol. of 0.5 % H $ PO % , distilled water and a final rinse with acetone. The discs were air-dried and placed in plastic scintillation vials containing 6 ml of Liquiscint prior to scintillation counting of radioactivity.
Measurement of binding of decavanadate to kemptide using UV-visible spectroscopy
All experiments were conducted using a Perkin-Elmer Lambda 2 spectrophotometer. Absorbance was measured at 300 nm. The final cuvette volume was 1 ml. All experiments were performed in triplicate. A 100 mM Mops buffer (pH 7.1, 0.625 mM V-atoms) was employed to give conditions similar to those in the enzyme assay. The vanadate decamer concentration was held constant at 62.5 µM, and the kemptide concentration was varied from 0 to 125 µM. 14 C-labelled N-acetylkemptide using phosphocellulose paper discs A 25 µl aliquot of N-["%C]acetylkemptide (400 µM ; 130 c.p.m.\ nmol) was pipetted on to a phosphocellulose paper disc and
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Scheme 1 Models A and B for the mechanism of PKA inhibition by decavanadate
Note that the uni-substrate systems illustrated represent a simplification of the bi-substrate nature of the PKA-catalysed reaction. All experiments were conducted with ATP in large excess, thereby enabling treatment of the kinetic data as for a uni-substrate reaction [41] . K, kemptide ; E, enzyme ; D, decavanadate.
allowed to sit for 10 s. The disc was subsequently completely immersed in 5 ml of a solution containing 100 mM Mops, 150 mM KCl, 12.5 mM MgCl # , 0.125 mg\ml BSA (pH 7.1) and various concentrations of decavanadate (0, 1, 2, 3 and 5 mM) for 4.5 min. The disc was removed, washed with water (4i600 ml), dried with acetone and counted for radioactivity. These experiments were performed in triplicate.
Measurement of binding of decavanadate to 32 P-labelled phosphokemptide using phosphocellulose paper discs
A solution of $#P-labelled phosphokemptide was prepared by incubating kemptide (20 µM) with PKA (1.25 nM) in the presence of 100 µM [γ-$#P]ATP (100 c.p.m.\pmol) (100 mM Mops, 150 mM KCl, 380 nM dithiothreitol and 0.125 mg\ml BSA at pH 7.1) for 6 min ; the reaction was then quenched with 10 µl of 150 mM EDTA. A 20 µl aliquot of phosphokemptide was then added to 20 µl of the decavanadate solution (final decavanadate concentrations 0, 0.5, 1.0, 2.0 and 4.0 mM). After 4.5 min, a 25 µl aliquot of this solution was pipetted on to a phosphocellulose disc. After 10 s, the discs were placed in a 10 % acetic acid solution for 1 h. After decantation of the acetic acid, the discs were washed with 4 vol. of 0.5 % H $ PO % , distilled water and a final rinse with acetone. The discs were air-dried and placed in plastic scintillation vials containing 6 ml of Liquiscint prior to scintillation counting of radioactivity. These experiments were peformed in triplicate.
Data analysis
The kinetic data were analysed using the programs EnzymeKinetics and EXCELL according to Model A in Scheme 1 ; the two programs yielded similar kinetic parameters (see Results and discussion section). The kinetic parameters using EXCELL were obtained by minimization of the variance between the calculated rates and the experimentally derived rates. This treatment assumes that the experimental rates can be approximated using a uni-substrate model, since ATP is present in large excess. Analysis of the kinetic data according to Model B was also conducted using EXCELL. The experimental data obtained under these conditions were minimized to a K m of 16p1 µM and used with both models. Kinetic parameters for a putative Model C (see the Results and discussion section) were also obtained using EXCELL.
RESULTS AND DISCUSSION
Vanadate has been shown to promote the formation of elevated levels of phosphoproteins, specifically those proteins that are phosphorylated on tyrosine residues [1] [2] [3] [4] [5] [6] . This has been ascribed to activation of protein kinase signal transduction pathways and\or inhibition of phosphotyrosine phosphatases [7] . However, relatively little work has been reported concerning the effects of vanadate, or of related species, on the activity of purified serine\threonine kinases [21] [22] [23] . We report here that both decavanadate and vanadium(IV) markedly alter the activity of PKA, albeit via different mechanisms. In contrast, vanadate, in a concentration range of 100 µM-40 mM, does not modulate the activity of this enzyme. These findings are important for several reasons. Studies by Catalan et al. [22] showed that vanadate promoted enhanced PKA activity in rat heart strips and increased the levels of this protein kinase in rat liver slices. This was ascribed, at least in part, to a vanadate-induced activation of adenylate cyclase, leading to higher levels of cAMP and resulting in the activation of the PKA signal transduction pathway. Gresser et al. [7] proposed a molecular mechanism that accounts for the effect of vanadate on tyrosine kinases that involves the formation of a vanadate ester with a tyrosine hydroxyl moiety. Interestingly, the three-dimensional structure of the serine\ threonine-specific PKA reveals the presence of two key tyrosine moieties in the active site [24] . Vanadate ester formation at Tyr-330 could conceivably interfere with substrate recognition, whereas an analogous reaction at Tyr-164 could preclude
Figure 1 PKA activity as a function of vanadate ($), decavanadate (#) and vanadium(IV) (=) concentrations
The kemptide concentration was 20 µM, and the ATP concentration was 100 µM (100 c.p.m./pmol). Vanadate was present at 0, 0.1, 0.5, 1.0, 3.0 and 10 mM, decavanadate at 0, 0.1, 0.5, 1.0 and 3.0 mM, and vanadyl at 0, 0.125, 0.25, 0.5 and 1.0 mM. Note that the result for vanadate at 10 mM is not shown.
Figure 2 Rate of kemptide phosphorylation by PKA as a function of total kemptide concentration
The total kemptide concentration was varied from 6.7 to 40 µM. The decavanadate concentrations employed were 0, 0.25, 0.50, 0.75, 1.0, 2.5 and 4.0 mM. A K i of 1.8p0.1 mM was obtained for decavanadate under the assumptions of Model A (see Scheme 1) using the data analysis described in the Experimental section. In addition, a plot of the slopes shown against the decavanadate concentration generated a linear replot with a K i value of 1.38p0.06 mM.
phosphoryl transfer due to possible deleterious electrostatic interactions with the active-site base Asp-166. However, vanadate, in the monomeric, dimeric, tetrameric or pentameric form, neither inhibited nor activated PKA (Figure 1 ). Based on these results, we can rule out the possibility that up to millimolar concentrations of vanadate can stimulate PKA activity by acting directly upon the enzyme.
Although vanadate failed to modulate PKA activity directly, decavanadate did exert a profound effect on the rate at which PKA phosphorylates kemptide. Decavanadate has been found to inhibit adenylate cyclase [25] , phosphorylase [26] and fructose-1,6-bisphosphate aldolase [18] , as well as the phosphotransferase enzymes hexokinase, adenylate kinase and phosphofructokinase [17] . Interestingly, a non-competitive inhibition pattern is elicited by decavanadate for the hexokinase-catalysed reaction with both ATP and glucose substrates [17] . In contrast we found that, in the case of PKA, decavanadate serves as a competitive inhibitor of the serine-containing peptide substrate kemptide (Figure 2) , an inhibition pattern that is surprising for two reasons. First, decavanadate represents the only example of an inorganic competitive inhibitor of a protein kinase peptide substrate. Secondly, competitive inhibition of kemptide phosphorylation is consistent with both inhibitor and peptide binding non-covalently to the same site on the enzyme surface. At first glance, such an interpretation appears indefensible. PKA has a special affinity for proteins (or peptides) that possess positively charged amino acid residues near the serine residue to be phosphorylated, whereas decavanadate is a negatively charged species. Nevertheless, various explanations for the competitive inhibition pattern can be offered. For example, it is possible that decavanadate can co-ordinate to a non-active-site region of the protein kinase and, in doing so, indirectly preclude phosphorylation of kemptide. This would suggest that decavanadate is capable of regulating protein kinase activity at a distant site. At the present time there is no evidence for this type of behaviour, nor has any other small molecule been described in the literature that is capable of regulating PKA in this fashion. Alternatively, decavanadate may prevent kemptide from binding to the enzyme by co-ordinating to a positively charged residue at or near the active site. Indeed, Arg-165 lies within the active-site region [24] . Non-covalent association of decavanadate with this residue might also disrupt the active-site structure to such an extent that phosphoryl transfer from ATP to peptide cannot proceed. Although decavanadate would be expected to be electrostatically repelled from negatively charged residues, previous studies have found that the decamer and related oxoanions can form covalent complexes with alkoxides and carboxylate groups [27, 28] . Consequently it is possible that decavanadate could reversibly form a covalent complex with an active-site residue in PKA (Model A, Scheme 1). Several such residues are available for complexation, such as the active-site base Asp-166 [24] . Alternatively, the negatively charged decavanadate could associate with the positively charged kemptide molecule in solution and thereby interfere with the incorporation of kemptide into the active site of PKA (Model B, Scheme 1). This model involves formation of a complex, KD, between kemptide (K) and decavanadate (D) with the formation constant K eq . Studies were conducted to distinguish between Models A and B.
The data obtained at various kemptide concentrations and at a constant ATP concentration for a series of decavanadate concentrations are illustrated in a Lineweaver-Burk doublereciprocal plot (Figure 2 ). The calculated rates in the presence of a competitive inhibitor (D) are defined as shown in eqn. (1) . In this relationship, the concentration of free kemptide ([K]) is equivalent to the total concentration of kemptide added to the assay mixture ([K] tot ). When the kinetic data were minimized according to the rate expression shown for Model A using the EXCELL program, a K i of 1.8p0.1 mM was obtained for decavanadate.
Alternatively, the negatively charged decavanadate may associate with the positively charged kemptide in solution, thereby leading to decreased enzyme activity by virtue of a decrease in the concentration of available kemptide (Model B). In short, the assumption that [ 
With Model B a K i value is not obtained, since decavanadate does not remove free enzyme from the assay solution by forming an enzyme-inhibitor complex, but rather removes free kemptide by forming a kemptide-decavanadate complex. However, Model B does yield a formation constant (550p50 M −" ) for the latter complex. Since the fit of the kinetic data to both models is excellent, alternative lines of evidence were sought to distinguish between these two modes of decavanadate inhibition of PKA.
As an aside, we note the possibility of a Model C, in which the kemptide-decavanadate complex serves as an inhibitor of PKA. Eqns. (1) and (2) The solution for each kemptide concentration was prepared by adding appropriate amounts of decavanadate stock solution, kemptide stock solution (or water) and buffer to give a final solution containing 100 mM Mops at pH 7.1.
and a formation constant of 550p50 M −" for KD complexformation, a K i value of 0.6p0.2 mM was obtained by minimization of the deviation of the calculated rates from the experimentally derived rates. However, this model suffers from several of the problems described in the discussion for Model A, as well as being less likely than Model B. In particular, PKA binding requires the presence of positively charged residues on the substrate or inhibitor. However, in the KD complex, these positive charges are presumably neutralized by the presence of decavanadate.
Decavanadate salts have been prepared with a large number of different cations. We prepared the crystalline salts of decavanadate with Na + , K + and NH
] and measured the absorbances of these complexes. The molar absorption coefficients for these crystalline salts are 11 000, 12 000 and 13 000 M −" :cm −" respectively. Since the absorbances of these complexes vary with the counter-cation in aqueous solution, it is possible that the addition of kemptide to a solution of decavanadate (which contains Na + and Mops buffer) would result in changes in absorbance should a KD complex be formed. This expectation is further supported by the fact that complexes formed between vanadate and di-and tri-ethanolamine are observable by UV-visible spectroscopy ; these complexes have formation constants that are similar in magnitude to that obtained for the KD complex using enzyme kinetics [29] . Indeed, there is a linear increase in decavanadate absorbance at 300 nm as a function of increasing kemptide concentration (Figure 3 ). Since kemptide alone has no absorbance at this wavelength, this observation is consistent with the hypothesis that decavanadate and kemptide, two oppositely charged species, interact (via the formation of a complex) in an aqueous environment. Reported molar absorption coefficients for other amine salts of decavanadate are consistent with the estimated molar absorption coefficient of 17 500 M −" :cm −" for the KD complex at 300 nm [30] .
We also examined the ability of decavanadate to prevent binding of "%C-labelled N-acetylkemptide to negatively charged phosphocellulose paper discs ( Figure 4) . As the concentration of decavanadate increased, the fraction of N-acetylkemptide bound to the phosphocellulose discs decreased. In short, decavanadate interferes with the ability of N-acetylkemptide to bind to a
Figure 4 Complex-formation between N-[ 14 C]acetylkemptide and phosphocellulose discs as a function of decavanadate concentration
Aliquots of N-[
14 C]acetylkemptide (10 nmol) were absorbed on to phosphocellulose paper discs, which were subsequently immersed in 5 ml of 100 mM Mops (pH 7.1), 150 mM KCl, 12.5 mM MgCl 2 , 0.125 mg/ml BSA and various concentrations of decavanadate (0, 1, 2, 3 and 5 mM) for 4.5 min. The discs were subsequently washed and counted for radioactivity. 32 P]ATP o100 µM [γ-32 P]ATP, 100 mM Mops, 150 mM KCl, 380 nM dithiothreitol and 0.125 mg/ml BSA at pH 7.1q and subsequently placed on to phosphocellulose paper discs with various concentrations of decavanadate (0, 0.5, 1.0, 2.0 and 4.0 mM). After 10 s, the discs were washed and counted for radioactivity.
Figure 5 Complex-formation between [ 32 P]phosphokemptide and phosphocellulose discs as a function of decavanadate concentration
negatively charged surface, an observation consistent with the notion that decavanadate precludes association of kemptide with the negatively charged substrate-binding region in PKA. The possibility that decavanadate might interfere with the binding of phosphorylated kemptide to the phosphocellulose discs was examined by measuring the affinity of phosphorylated kemptide for these negatively charged discs in the presence of various concentrations of decavanadate. Decavanadate had little effect on the ability of phosphokemptide to bind to these discs ( Figure  5 ), which is consistent with the notion that the negatively charged phosphate moiety interferes with decavanadate-phosphokemptide complex-formation. In short, we conclude that enzyme kinetics, UV-visible spectroscopy and phosphocellulose binding experiments are all consistent with the model that decavanadate exerts its inhibitory effect on PKA by coordinating the peptide substrate.
In spite of the evidence for decavanadate-kemptide com-
Figure 6 Molecular structures of decavanadate (top) and vanadate tetramer (bottom)
Note that three of the vanadium atoms of decavanadate and one of the vanadium atoms of vanadate tetramer are hidden from view. Structures were characterized by X-ray crystallography.
plexation in aqueous solution, it is evident that the charged nature of the decavanadate species is not the sole source of its inhibitory behaviour, since the vanadate tetramer [present at a concentration of approx. 10 mM at the highest concentration of vanadate (40 mM) employed] is negatively charged but is ineffective as a protein kinase inhibitor. The molecular structures of many decavanadate salts are well known (shown by the Chem 3D drawing of the X-ray structure in Figure 6 ) [31] . The decamer is a rigid molecule that is 8.8 A H (0.88 nm) long and 7.7 A H wide. The corresponding structure of the vanadate tetramer in solution is somewhat less well characterized, although structural, solution and enzymic data favour the cyclic structure shown in Figure 6 [32, 33] . Should the solution structure be similar to the solid-state structure, this ion will have dimensions of 7.1 A H and 5.5 A H , although it is relatively flexible by flattening its ring system. Thus it is possible that the inhibitory behaviour of decavanadate and the corresponding inactivity of the tetramer is related to differences in the distances between the oxyanions on the surfaces of these molecules. Both the decamer and tetramer have several charge distances of approx. 5 A H . In addition, the tetramer has all short oxygen distances that vary from 2.6 to 2.9 A H . In contrast, the decamer has sets of short oxygen-oxygen distances of various lengths (2.8, 3.2 and 3.6 A H ), which may enable it to hydrogenbond more effectively to the side chains of residues such as arginine. Interestingly, there is evidence that the vanadate tetramer co-ordinates to proteins in a fashion that does not require the presence of an arginine residue [34, 35] , whereas arginine may be critical for the interaction of decavanadate with proteins such as phosphorylase and glycoprotein PG120 (involved in HIV infectivity) [36] .
Vanadate is reduced to vanadyl cation upon entry into the cytoplasm [37] . The physiological effects of vanadium are commonly attributed to the vanadyl cation. However, some evidence suggests that vanadate may also exist intracellularly [38] . Since we have demonstrated that vanadate, in the monomeric, dimeric, tetrameric and pentameric oxoanions, has no effect on the activity of PKA, any direct in i o effects of vanadate on this enzyme would be mediated via the formation of VO# + . Indeed, V% + is a good inhibitor of PKA, exhibiting an apparent IC &! of 366p10 µM. However, in the light of the solution chemistry of vanadium(IV) in the neutral pH range [29, 38] , the concentration of free hydrated VO# + is significantly less than 366 µM, corresponding to a low micromolar or submicromolar affinity of this cation for PKA.
VO# + has previously been found to bind to the Mg# + -binding sites of two enzymes, namely pyruvate kinase [19] and Sadenosylmethionine synthetase [39] . Accordingly, we explored the possibility that VO# + could substitute for Mg# + in the protein kinase-catalysed phosphorylation of kemptide. A plot of reaction velocity against V% + concentration in the absence of Mg# + ( Figure  7) indicates that VO# + can substitute for Mg# + . Furthermore, vanadium(IV) concentrations above 100 µM were inhibitory. We and others have noted that the optimum concentration of Mg# + is 2.5 mM [40] [41] [42] [43] ; at concentrations greater than this, Mg# + is likewise inhibitory. At low concentrations, Mg# + co-ordinates to the β-and γ-phosphate groups of ATP, an interaction that is essential for enzymic activity. At higher concentrations, a second Mg# + binds to the enzyme active site, bridging the α-and γ-phosphates of ATP with the side chain of Asn-171 and producing a decrease in the rate at which phosphorylated kemptide is produced [24] . Since added VOSO % produces a similar inhibitory effect at concentrations above 100 µM, it is possible that two V% + ions can simultaneously bind to the active site as well. However, due to the complex nature of vanadium solution chemistry at neutral pH, as well as the series of vanadium complexes that form in the presence of buffers and nucleotides [38] , the specific nature of this inhibition may or may not be analogous to that observed with Mg# + . Although we have not yet determined the exact nature of the form of the vanadium(IV) species that inhibits PKA, these results clearly show that some form of aqueous vanadium(IV) interacts with this protein. These findings are consistent with the recent report showing that a vanadium(IV)-glutathione complex inhibits this enzyme [44] , and led us to explore further the nature of the interaction of PKA with added VOSO % . Although a detailed analysis of the behaviour of vanadium(IV) species in solution in the presence of buffer and other assay additives is beyond the scope of this study, we compared the effects of equivalent concentrations of Mg# + and VOSO % on the activity of PKA. In the presence of 100 µM added VOSO % , the reaction proceeded with a V max of 0.26p0.02 µmol\min per mg and a K m for kemptide of 69p13 µM. By comparison, 100 µM Mg# + gave a K m of 44p3 µM and a V max of 10.0p0.4 µmol\min per mg. Although VOSO % promotes PKA-catalysed phosphorylation of kemptide in the absence of Mg# + [thereby demonstrating that a vanadium(IV) species serves as a participating cofactor in this reaction], the efficacy (i.e. k cat \K m ) of the reaction in the presence of V% + is less than 2 % of that exhibited in the presence of Mg# + . Consequently, the observed inhibitory effect of added VOSO % is due to the decreased rate of kemptide phosphorylation when V% + substitutes for Mg# + .
We conclude that decavanadate inhibits PKA activity by associating with the kinase substrate. This mechanism of inhibition is unprecedented, since it represents the first example of such an ' anti-substrate ' inhibitor for a serine\threonine-specific protein kinase and the first example of such a species that is entirely inorganic. Since derivatives of decavanadate can be synthesized [27] , it should be possible to prepare more potent analogues of this potentially important new class of inhibitor. Furthermore, derivatization of decavanadate could be employed to promote specificity for individual kinase substrates. These inhibitors would enjoy the advantage of precluding phosphorylation of specific targets without interfering with the ability of the protein kinase to phosphorylate other proteins. In contrast to the mechanism of action of decavanadate, vanadium(IV) alters the activity of PKA by serving as a Mg# + replacement. These results demonstrate that the influence of vanadium oxoions is not limited to the enzymes responsible for the levels of phosphotyrosine in intact proteins, but extends into the realm of the serine\threonine-specific protein kinases as well. Furthermore, we have shown that oxovanadium ions can inhibit PKA by a variety of different mechanisms.
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